

FOI2918

20th February 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Response:

Please see figures for current patients

• Adalimumab – Humira -	7
• Adalimumab Biosimilar -	190
• Etrasimod -	0
• Filgotinib -	0
• Golimumab -	1
• Infliximab – Remicade -	0
• Infliximab Biosimilar -	97
• Mirikizumab -	0
• Ozanimod -	0
• Risankizumab -	0
• Tofacitinib -	4
• Upadacitinib -	20
• Ustekinumab – Stelara -	28
• Ustekinumab Biosimilar -	68
• Vedolizumab -	104

Q2. Could you please provide the numbers of patients treated for Crohn's Disease in the last 3 months with the following biologic drugs:

Response:

Please see figures for current patients

• Adalimumab – Humira -	7
• Adalimumab Biosimilars -	123
• Golimumab -	0
• Infliximab – Remicade -	0
• Infliximab Biosimilar -	45
• Risankizumab -	0
• Upadacitinib -	11
• Ustekinumab – Sterala -	8
• Ustekinumab Biosimilar -	59

- **Vedolizumab -**

51

Email: foi.team@southerntrust.hscni.net